var data={"title":"Sodium bicarbonate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium bicarbonate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6962?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">see &quot;Sodium bicarbonate: Drug information&quot;</a> and <a href=\"topic.htm?path=sodium-bicarbonate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium bicarbonate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50782002\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pfizer Extended Expiration Dates for Emergency Syringe Shortages</span>\n      <span class=\"collapsible-date\">- updated November 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has alerted health care providers of extended expiration dates for certain injectable drug products manufactured by Hospira (a Pfizer company) which may be used beyond the labeled expiration dates to assist with the ongoing critical shortages of injectable drugs used in critical care. Select lot numbers of atropine sulfate injection, dextrose 50%, epinephrine injection, and sodium bicarbonate are eligible for use beyond the labeled expiration date if they have been and will continue to be stored according to the labeled conditions<b>. </b></p>\n        <p style=\"text-indent:0em;\">Further information, including specific products, lot numbers, and extended expiration dates, may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPGtnB1wPEGG5AqBctyC78FXNni9GZNAqH+dg03OunIQVFis/VBQ2KMfj5sKJ1X0d3K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=12795\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm</a><b>.</b></p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221612\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neut</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062178\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Alkalinizing Agent, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Alkalinizing Agent, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antacid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sodium Salt</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445044\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Rapid administration at a high concentration may be associated with fluctuation in cerebral blood flow and possibly ICH; carefully consider clinical need before administering (Aschner 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Metabolic  acidosis:</b> IV: Dosage should be based on the following formula if blood gases and pH measurements are available. These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 to prevent overalkalinization (Androgue 2006; Furhman 2011): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> HCO<sub>3</sub><sup>-</sup>(mEq) = 0.3 x weight (kg) x base deficit (mEq/L) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> HCO<sub>3</sub><sup>-</sup>(mEq) = 0.5 x weight (kg) x [24 - serum HCO<sub>3</sub><sup>-</sup>(mEq/L)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Usual dosage: 1 to 2 mEq/kg/dose (Berg 2010). In 55 asphyxiated neonates, a fixed dose of 1.8 mEq/kg/dose over 3 to 5 minutes administered within first 5 minutes of life did not show clinical benefit (eg, survival, acid-base status, neurodevelopmental outcomes) compared to control group (Lokesh 2004; Murki 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062172\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">see &quot;Sodium bicarbonate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose should be individualized to patient response and target parameters for condition being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antacid: Note:</b> Chronic antacid therapy not recommended for management of GERD in pediatric patients (AAP [Lightdale 2013]; NASPGHAN/ESPGHAN [Vandenplas 2009]). Children &ge;5 years and Adolescents: Oral powder: Oral: <sup>1</sup>/<sub>2</sub>  teaspoonful/dose; may repeat up to every 2 hours not to exceed 7 doses in 24 hours, and do not use longer than 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiac arrest (PALS guidelines):</b> Infants, Children, and Adolescents: IV, Intraosseous: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases; in infants and children &lt;2 years of age, the 4.2% (0.5 mEq/mL) solution should be used. <b>Note:</b> If intraosseous route is used for administration and is subsequently used to obtain blood samples for acid-base analysis, results will be inaccurate (AHA [Kleinman 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: Routine use of sodium bicarbonate (NaHCO<sub>3</sub>) is not recommended.</b> May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions. <b>Note:</b> In some cardiac arrest situations (eg, metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose), sodium bicarbonate may be beneficial (AHA [Kleinman 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic kidney disease (CKD)  acidosis:</b> Limited data available: <b>Note:</b> Initiate if serum bicarbonate &lt;22 mEq/L (KDIGO 2012): Infants, Children, and Adolescents: Oral: Initial dose based on serum bicarbonate levels (see following equation); may divide dose for tolerability (Kraut 2011); adjust dose to maintain serum bicarbonate within the targeted normal range (eg, children: 22 to 23 mEq/L; adults: 24 to 25 mEq/L); undertreatment should be avoided due to negative effects of acidosis on growth (KDIGO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HCO<sub>3</sub><sup>-</sup>(mEq) = 0.5 x weight (kg) x [desired HCO<sub>3</sub><sup>-</sup> (mEq/L) - serum HCO<sub>3</sub><sup>-</sup>(mEq/L)] </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperkalemia; adjunct:</b> Limited data available; efficacy results variable:  Infants, Children, and Adolescents: IV: 1 to 2 mEq/kg/dose has been used  to redistribute extracellular potassium into cells based on physiologic understanding (Hegenbarth 2008); however, some data has shown efficacy lacking for use in acute, early treatment of hyperkalemia (ie, 60 minutes); in adult dialysis patients, while short infusions were shown to increase serum bicarbonate, they were not shown to reduce serum potassium (Ahee 2000; Blumberg 1988; Gutierrez 1991; Kim 1996; Weisberg 2008); some efficacy was observed with a long duration hypertonic bicarbonate infusion (eg, 150 mEq/L in D5W) used as rehydration fluid and/or in presence of  metabolic acidosis (Weiner 1998; Weisberg 2008); serum Na should also be monitored closely </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Metabolic acidosis, acute:</b> Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Blood-gas directed dosing (equations):</i> IV: These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2   to prevent overalkalinization (Androgue 2006; Furhman 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HCO<sub>3</sub><sup>-</sup>(mEq) = 0.3 x weight (kg) x base deficit (mEq/L) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HCO<sub>3</sub><sup>-</sup>(mEq) = 0.5 x weight (kg) x [24 - serum HCO<sub>3</sub><sup>-</sup>(mEq/L)] </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Administer <sup>1</sup>/<sub>2</sub> calculated dose initially, then remaining  <sup>1</sup>/<sub>2</sub> dose over the next 24 hours; monitor pH, serum HCO<sub>3</sub>-, and clinical status</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Weight-directed dosing (if acid-base status is not available):</i> Infants, Children, and Adolescents:  IV, Intraosseous: 1 to 2 mEq/kg/dose (Hegenbarth 2008), in older Children (&gt;2 years) and Adolescents: 2 to 5 mEq/kg IV infusion over 4 to 8 hours; subsequent doses should be based on patient's acid-base status </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neutralization local (dental) anesthetic (lidocaine with epinephrine):</b> Neutralizing additive: Mix 10 parts anesthetic (lidocaine with epinephrine) to 1 part 8.4% sodium bicarbonate</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 0.18 mL sodium bicarbonate to 1.8 mL cartridge of lidocaine 2% with epinephrine 1:50,000 or 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 2 mL sodium bicarbonate to 20 mL vial of lidocaine 2% with epinephrine 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 3 mL sodium bicarbonate to 30 mL vial of lidocaine 2% with epinephrine 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 5 mL sodium bicarbonate to 50 mL vial of lidocaine 2% with epinephrine 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal tubular acidosis (RTA):</b> Limited data available: <b>Note:</b> Dose should be individualized based on urinary bicarbonate excretion (degree depends on type of RTA), serum bicarbonate, and possibly age-related factors; undertreatment should be avoided due to negative effects of acidosis on growth (KDIGO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Distal; type 1:</i> Dose requirements may vary with age; some data suggests infants and children &lt;6 years require higher daily dose than older children (Rodriguez-Soriano 1982); daily dose should replace urinary excretion and endogenous production (McSherry 1972, Rodriguez-Soriano 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: Oral: Usual range: 5 to 8 mEq/kg/day (Rodriguez-Soriano 2002); reported range: 3.9 to 10 mEq/kg/day (Rodriguez-Soriano 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: Oral: Initial: At least 3 mEq/kg/day; usual initial range: 3 to 4 mEq/kg/day; titrate as necessary (Rodriguez-Soriano 1982, Rodriguez-Soriano 2002, Santos 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Proximal, type 2:</i> Infants, Children, and Adolescents: Oral: Initial: 5 to 10 mEq/kg/day in divided doses; usual range: 10 to 20 mEq/kg/day; titrate as necessary to target  serum bicarbonate (Chan 2001; Rodriguez-Soriano 2002) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin protectant; relief of minor irritation: Note:</b> Notify physician if no symptom resolution within 7 days, or if symptoms reappear after an initial resolution. Children &ge;2 years and Adolescents: Topical: Oral powder (baking soda):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bath soak: Dissolve 1 to 2 cups in tub of warm water, soak for 10 to 30 minutes; pat skin dry</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Compress or wet dressing: Mix powder with water; soak clean soft cloth with mixture, apply cloth loosely to affected area for 15 to 30 minutes; may repeat as needed or as directed by physician.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Paste: Mix powder with water to form a paste, apply to the affected area of skin as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tricyclic antidepressant (TCA, Na channel blocker), overdose:</b> Limited data available: Infants, Children, and Adolescents: IV, Intraosseous: 1 to 2 mEq/kg/dose; titrate to maintain serum pH 7.45 to 7.55, follow with 150 mEq NaHCO<sub>3</sub>/L infusion to maintain targeted pH (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antacid:</b> Oral: 325 mg to 2 g 1 to 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiac arrest</b> (ACLS, [Vanden Hoek 2010]): IV: Initial: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Routine use of NaHCO3 is not recommended.</b> May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions. <b>Note:</b> In some cardiac arrest situations (eg, metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose); sodium bicarbonate may be beneficial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic renal failure:</b> Oral: Initiate when plasma HCO<sub>3</sub><sup>-</sup> &lt;15 mEq/L Start with 20 to 36 mEq/day in divided doses, titrate to bicarbonate level of 18 to 20 mEq/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperkalemia</b> (ACLS, [Vanden Hoek 2010]): IV: 50 mEq over 5 minutes (as appropriate, consider methods of enhancing potassium removal/excretion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Metabolic acidosis:</b> IV: Dosage should be based on the following formula if blood gases and pH measurements are available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HCO<sub>3</sub><sup>-</sup>(mEq) = 0.5 x weight (kg) x [24 - serum HCO<sub>3</sub><sup>-</sup>(mEq/L)] <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HCO<sub>3</sub><sup>-</sup>(mEq) = 0.5 x weight (kg) x [desired increase in serum HCO<sub>3</sub><sup>-</sup>(mEq/L)]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Administer <sup>1</sup>/<sub>2</sub> dose initially, then remaining  <sup>1</sup>/<sub>2</sub> dose over the next 24 hours; monitor pH, serum HCO<sub>3</sub>-, and clinical status. <b>Note:</b> These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 and a plasma bicarbonate level of ~10 mEq/L to prevent overalkalinization.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If acid-base status is not available: 2 to 5 mEq/kg IV infusion over 4 to 8 hours; subsequent doses should be based on patient's acid-base status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neutralize lidocaine with epinephrine dental anesthetic:</b> Neutralizing additive: Mix 10 parts anesthetic (lidocaine with epinephrine) to 1 part 8.4% sodium bicarbonate</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 0.18 mL sodium bicarbonate to 1.8 mL cartridge of lidocaine 2% with epinephrine 1:50,000 or 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 2 mL sodium bicarbonate to 20 mL vial of lidocaine 2% with epinephrine 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 3 mL sodium bicarbonate to 30 mL vial of lidocaine 2% with epinephrine 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Add 5 mL sodium bicarbonate to 50 mL vial of lidocaine 2% with epinephrine 1:100,000</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal tubular acidosis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Distal:</i> 0.5 to 2 mEq/kg/day in 4 to 5 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Proximal:</i> Initial: 5 to 10 mEq/kg/day; maintenance: Increase as required to maintain serum bicarbonate in the normal range</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urine alkalinization:</b> Oral: Initial: 48 mEq (4 g), then 12 to 24 mEq (1 to 2 g) every 4 hours; dose should be titrated to desired urinary pH; doses up to 16 g/day (200 mEq) in patients &lt;60 years and 8 g (100 mEq) in patients &gt;60 years</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221592\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic:  (1 g, 120 g, 454 g, 500 g, 1000 g, 2500 g, 10000 g, 12000 g, 25000 g, 45000 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neut: 4% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4.2% (5 mL, 10 mL); 7.5% (50 mL); 8.4% (10 mL, 50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 325 mg, 650 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221578\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963630\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">see &quot;Sodium bicarbonate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium bicarbonate solution 4.2% [42 mg/mL] provides 0.5 mEq/mL each of sodium and bicarbonate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium bicarbonate solution 7.5% [75 mg/mL] provides 0.9 mEq/mL each of sodium and bicarbonate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium bicarbonate solution 8.4% [84 mg/mL] provides 1 mEq/mL each of sodium and bicarbonate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062182\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer 1 to 3 hours after meals </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder (including baking soda): Measure dose exactly, mix with adequate amount of water (eg, <sup>1</sup>/<sub>2</sub> teaspoon baking soda with 4 ounces of water), allow to dissolve completely prior to administration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Direct IV injection: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates and Infants: Administer 0.5 mEq/mL solution (either using the 0.5 mEq/mL solution undiluted or dilute the 1 mEq/mL solution 1:1 with SWFI); administer slowly, \tmaximum rate: 10 mEq/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children, Adolescents, and Adults: Administer 1 mEq/mL solution; administer slowly  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV infusion: Must be diluted prior to administration; infusion time variable based upon use; for metabolic acidosis,  infusions over 2 to 8 hours have been suggested; maximum rate of administration: 1 mEq/kg/hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vesicant (at concentrations &ge;8.4%); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Paste, compress/dressing: Apply to clean affected area </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221607\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store injection at room temperature. Protect from heat and from freezing. Use only clear solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neutralizing additive (dental use): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062181\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Relieve conditions of gastric hyperacidity including acid indigestion, heartburn, sour stomach, or upset stomach associated with these symptoms (OTC: Powder: FDA approved in ages &ge;5 years and adults; tablets: FDA approved in adults); has also been used for management of renal tubular acidosis, and acidosis secondary to chronic kidney disease. <b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Management of metabolic acidosis; as an alkalinization agent for the urine; management of overdose of certain drugs, including tricyclic antidepressants and aspirin (All indications: FDA approved in pediatric patients [age not specified] and adults); has also been used for management of hyperkalemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neutralizing additive: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local (dental) anesthetic additive (Lidocaine/epinephrine): Adjust lidocaine with epinephrine solution to more physiologic pH to improve onset of analgesia and reduce injection site pain (FDA approved in all ages). <b>Note:</b> Consult lidocaine/epinephrine product labeling for specific FDA approval ages.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Parenteral neutralizing additive (eg, Neut): Additive to acidic intravenous solutions to raise pH and reduce patient discomfort and incidence of phlebitis (FDA approved in all ages). <b>Note:</b> Consult product specific labeling of acidic intravenous solution for specific FDA approval ages.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Used as a skin protectant and minor irritation relief due to poison ivy, oak, and sumac or insect bites (OTC: Powder: FDA approved in ages &ge;2 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221644\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure (exacerbation), edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebral hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis (intracranial), hypernatremia, hypocalcemia, hypokalemia, metabolic alkalosis, milk-alkali syndrome (especially with renal dysfunction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, eructation, flatulence (oral administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tetany</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221599\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalosis, hypernatremia, severe pulmonary edema, hypocalcemia, unknown abdominal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neutralizing additive (dental use): Not for use as a systemic alkalizer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221582\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant (at concentrations &ge;8.4%); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation (tissue necrosis may occur due to hypertonicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cirrhosis: Use with caution in patients with cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Edema: Use with caution in patients with edema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure: Use with caution in patients with heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peptic ulcer disease: Not to be used in treatment of peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may cause sodium retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Not the antacid of choice for the elderly because of sodium content and potential for systemic alkalosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Rapid administration in neonates, infants, and children &lt;2 years of age has led to hypernatremia, decreased CSF pressure, and intracranial hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection: <b>Use of IV NaHCO</b><sub>3</sub>  <b>should be reserved for documented metabolic acidosis and for hyperkalemia-induced cardiac arrest.</b> Routine use in cardiac arrest is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300051\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221587\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12795&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Antacids may decrease the serum concentration of Acalabrutinib.  Management: Separate administration of acalabrutinib from the administration of any antacids by at least 2 hours in order to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AcetaZOLAMIDE: May enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Antacids may decrease the absorption of Atazanavir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Antacids may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered while fasting at least 2 hours before antacids. Giving with or 2 hours after antacids is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: Antacids may diminish the therapeutic effect of Bismuth Subcitrate.  Management: Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismuth dicitrate) administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Antacids may decrease the absorption of Bromperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Captopril: Antacids may decrease the serum concentration of Captopril. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Antacids may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Antacids may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Antacids may decrease the absorption of Dasatinib. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Sodium Bicarbonate may diminish the arrhythmogenic effect of Flecainide. Sodium Bicarbonate may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosinopril: Antacids may decrease the serum concentration of Fosinopril.  Management: The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Antacids may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of an antacid, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyoscyamine: Antacids may decrease the serum concentration of Hyoscyamine.  Management: Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Antacids may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: Antacids may diminish the therapeutic effect of Lanthanum. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir.  Management: Separate the administration of ledipasvir and antacids by 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Sodium Bicarbonate may increase the excretion of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Antacids may diminish the therapeutic effect of Methenamine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Antacids may decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption.  Management: Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Antacids may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of antacids in combination with pazopanib whenever possible.  Separate doses by several hours if antacid treatment is considered necessary.  The impact of dose separation has not been investigated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration.  Separating administer of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate.  Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Antacids may decrease the excretion of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine. Administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Antacids may decrease the serum concentration of Riociguat.  Management: Separate the administration of antacids and riociguat by at least 1 hour in order to minimize any potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Antacids may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sotalol: Antacids may decrease the serum concentration of Sotalol.  Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antacids may decrease the serum concentration of Sulpiride.  Management: Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Antacids may decrease the absorption of Tetracyclines.  Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Antacids may decrease the serum concentration of Velpatasvir.  Management: Separate administration of velpatasvir and antacids by at least 4 hours.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13888241\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Campbell 2009; Jeejeebhoy [AHA] 2015). Antacids containing sodium bicarbonate should not be used during pregnancy due to their potential to cause metabolic alkalosis and fluid overload (Mahadevan 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062177\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes including calcium, urinary pH, arterial blood gases (if indicated)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221581\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dissociates to provide bicarbonate ion which neutralizes hydrogen ion concentration and raises blood and urinary pH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Neutralizing additive (dental use): Increases pH of lidocaine and epinephrine solution to improve tolerability and increase tissue uptake</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221598\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 15 minutes; IV: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: 1 to 3 hours; IV: 8 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062187\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">1 mEq NaHCO<sub>3</sub> is equivalent to 84 mg; each g of NaHCO<sub>3</sub> provides 12 mEq each of sodium and bicarbonate ions; the osmolarity of 0.5 mEq/mL is 1,000 mOsm/L and 1 mEq/mL is 2,000 mOsm/L</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Baking Soda powder: Each teaspoon contains 59 mEq of sodium and 59 mEq of bicarbonate (Al-Abri 2013; Taal 2012)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oral tablets (650 mg):  Each 650 mg tablet contains 7.7 mEq of sodium and 7.7 mEq of bicarbonate </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5687043\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neut Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (5 mL): $9.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sodium Bicarbonate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.2% (5 mL): $3.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5% (50 mL): $3.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.4% (50 mL): $10.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sodium Bicarbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (1000): $28.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">650 mg (1000): $13.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221602\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Betsol &quot;Z&quot; (MX);</li>\n      <li>Natrium bicarbonicum (PL);</li>\n      <li>Sodibic (AU);</li>\n      <li>Solunate (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. <i>J Accid Emerg Med</i>. 2000;17(3):188-191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/10819381 /pubmed\" target=\"_blank\" id=\"10819381 \">10819381 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adrogu&eacute; HJ. Metabolic acidosis: pathophysiology, diagnosis and management. <i>J Nephrol</i>. 2006;19(Suppl 9):S62-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/16736443 /pubmed\" target=\"_blank\" id=\"16736443 \">16736443 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aschner JL and Poland RL, &quot;Sodium Bicarbonate: Basically Useless Therapy,&quot; <i>Pediatrics</i>, 2008, 122(4):831-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/18829808/pubmed\" target=\"_blank\" id=\"18829808\">18829808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berg CS, Barnette AR, Myers BJ, et al, &quot;Sodium Bicarbonate Administration and Outcome in Preterm Infants,&quot; <i>J Pediatr</i>, 2010, 157(4):684-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/20580021/pubmed\" target=\"_blank\" id=\"20580021\">20580021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumberg A, Weidmann P, Shaw S, Gn&auml;dinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. <i>Am J Med</i>. 1988;85(4):507-512. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/3052050 /pubmed\" target=\"_blank\" id=\"3052050 \">3052050 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell TA and Sanson TG, &quot;Cardiac Arrest and Pregnancy,&quot; <i>J Emerg Trauma Shock</i>, 2009, 2(1):34-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/19561954/pubmed\" target=\"_blank\" id=\"19561954\">19561954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan JC, Scheinman JI, Roth KS. Consultation with the specialist: renal tubular acidosis. <i>Pediatr Rev</i>. 2001;22(8):277-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/11483854 /pubmed\" target=\"_blank\" id=\"11483854 \">11483854 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gutierrez R, Schlessinger F, Oster JR, Rietberg B, Perez GO. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. <i>Miner Electrolyte Metab</i>. 1991;17(5):297-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/1668124 /pubmed\" target=\"_blank\" id=\"1668124 \">1668124 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/18245435 /pubmed\" target=\"_blank\" id=\"18245435 \">18245435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humco sodium bicarbonate powder [prescribing information]. Texarkana, TX: Humco; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate</i>, Washington, DC: National Academy Press, 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim HJ. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. <i>Nephron</i>. 1996;72(3):476-482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/8852501/pubmed\" target=\"_blank\" id=\"8852501\">8852501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lightdale JR, Gremse DA, Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-1695.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/23629618 /pubmed\" target=\"_blank\" id=\"23629618 \">23629618 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lokesh L, Kumar P, Murki S, et al, &quot;A Randomized Controlled Trial of Sodium Bicarbonate in Neonatal Resuscitation-Effect on Immediate Outcome,&quot; <i>Resuscitation</i>, 2004, 60(2):219-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15036741/pubmed\" target=\"_blank\" id=\"15036741\">15036741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, &quot;Gastrointestinal Medications in Pregnancy,&quot;<i> Best Pract Res Clin Gastroenterol</i>, 2007, 21(5):849-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/17889812/pubmed\" target=\"_blank\" id=\"17889812\">17889812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McSherry E, Sebastian A, Morris RC Jr. Renal tubular acidosis in infants: the several kinds, including bicarbonate-wasting, classic renal tubular acidosis. <i>J Clin Invest</i>. 1972;51(3):499-514.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/5011097 /pubmed\" target=\"_blank\" id=\"5011097 \">5011097 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murki S, Kumar P, Lingappa L, et al, &quot;Effect of a Single Dose of Sodium Bicarbonate Given During Neonatal Resuscitation at Birth on the Acid-Base Status on First Day of Life,&quot;<i> J Perinatol</i>, 2004, 24(11):696-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15318251/pubmed\" target=\"_blank\" id=\"15318251\">15318251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neut sodium bicarbonate solution [prescribing information]. Lake Forest, IL: Hospira, Inc; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novaplus sodium bicarbonate injection [prescribing information].  Lake Forest, IL: Hospira, Inc; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodr&iacute;guez Soriano J. Renal tubular acidosis: the clinical entity. <i>J Am Soc Nephrol</i>. 2002;13(8):2160-2170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/12138150 /pubmed\" target=\"_blank\" id=\"12138150 \">12138150 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodr&iacute;guez-Soriano J, Vallo A, Castillo G, Oliveros R.  Natural history of primary distal renal tubular acidosis treated since infancy. <i>J Pediatr</i>. 1982;101(5):669-676.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/7131138 /pubmed\" target=\"_blank\" id=\"7131138 \">7131138 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos F, Chan JC. Renal tubular acidosis in children. Diagnosis, treatment and prognosis. <i>Am J Nephrol</i>. 1986;6(4):289-295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/3777038 /pubmed\" target=\"_blank\" id=\"3777038 \">3777038 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium bicarbonate 5 gr [prescribing information]. Duluth GA: Rugby Laboratories, Inc; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium bicarbonate injection [prescribing information]. El Monte, CA: International Medication Systems, Limited; January 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium bicarbonate injection, solution [prescribing information]. Lake Forest, IL: Hospira, Inc; June 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium bicarbonate neutralizing additive solution [prescribing information]. Los Gatos, CA: Onpharma; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BA, eds. <i>Brenner and Rector's The Kidney</i>. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2009;49(4):498-547.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/19745761 /pubmed\" target=\"_blank\" id=\"19745761 \">19745761 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weisberg LS. Management of severe hyperkalemia. <i>Crit Care Med</i>. 2008;36(12):3246-3251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/18936701 /pubmed\" target=\"_blank\" id=\"18936701 \">18936701 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12795 Version 172.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50782002\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221612\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062178\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445044\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062172\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221592\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F221578\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963630\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062182\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F221607\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062181\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221644\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221599\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221582\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300051\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F221587\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13888241\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062177\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221581\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F221598\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1062187\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5687043\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F221602\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12795|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">Sodium bicarbonate: Drug information</a></li><li><a href=\"topic.htm?path=sodium-bicarbonate-patient-drug-information\" class=\"drug drug_patient\">Sodium bicarbonate: Patient drug information</a></li></ul></div></div>","javascript":null}